Comparing Canadian and United States opioid agonist therapy policies.
Opioid agonist therapy
Opioid use disorder
MetadataShow full item record
AbstractCanada and the United States (U.S.) face an opioid use disorder (OUD) and opioid overdose epidemic. The most effective OUD treatment is opioid agonist therapy (OAT)-buprenorphine (with and without naloxone) and methadone. Although federal approval for OAT occurred decades ago, in both countries, access to and use of OAT is low. Restrictive policies and complex regulations contribute to limited OAT access. Through a non-systematic literature scan and a review of publicly available policy documents, we examined and compared OAT policies and practice at the federal (Canada vs. U.S.) and local levels (British Columbia [B.C.] vs. Oregon). Differences and similarities were noted between federal and local OAT policies, and subsequently OAT access. In Canada, OAT policy control has shifted from federal to provincial authorities. Conversely, in the U.S., federal authorities maintain primary control of OAT regulations. Local OAT health insurance coverage policies were substantively different between B.C. and Oregon. In B.C., five OAT options were available, while in Oregon, only two OAT options were available with administrative limitations. The differences in local OAT access and coverage policies between B.C. and Oregon, may be explained, in part, to the differences in Canadian and U.S. federal OAT policies, specifically, the relaxation of special federal OAT regulatory controls in Canada. The analysis also highlights the complicating contributions, and likely policy solutions, that exist within other drug policy sub-domains (e.g., the prescription regime, and drug control regime) and broader policy domains (e.g., constitutional rights). U.S. policymakers and health officials could consider adopting Canada's regulatory policy approach to expand OAT access to mitigate the harms of the ongoing opioid overdose epidemic.
- Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States.
- Authors: Davis CS, Carr DH
- Issue date: 2019 Nov
- The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
- Authors: Socias ME, Ahamad K, Le Foll B, Lim R, Bruneau J, Fischer B, Wild TC, Wood E, Jutras-Aswad D
- Issue date: 2018 Jun
- Determinants of selection into buprenorphine/naloxone among people initiating opioid agonist treatment in British Columbia.
- Authors: Homayra F, Hongdilokkul N, Piske M, Pearce LA, Zhou H, Min JE, Krebs E, Nosyk B
- Issue date: 2020 Feb 1
- Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018.
- Authors: Krebs E, Homayra F, Min JE, MacDonald S, Gold L, Carter C, Nosyk B
- Issue date: 2021 Aug 1
- Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
- Authors: Burns RM, Pacula RL, Bauhoff S, Gordon AJ, Hendrikson H, Leslie DL, Stein BD
- Issue date: 2016